<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A total of 139 young <z:hpo ids='HP_0001297'>stroke</z:hpo> patients were consecutively examined and tested for <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (APLA) to evaluate the role of these antibodies in <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> before the age of 45 </plain></SENT>
<SENT sid="1" pm="."><plain>APLA were found in 28.8% of patients </plain></SENT>
<SENT sid="2" pm="."><plain>Two factors, hypertriglyceridaemia and <z:e sem="disease" ids="C0085762" disease_type="Mental or Behavioral Dysfunction" abbrv="aca">alcohol abuse</z:e>, were significantly more frequent in patients with a positive APLA test </plain></SENT>
<SENT sid="3" pm="."><plain>The demographic characteristics, other risk factors, history of prior thrombotic events and distribution of aetiopathogenic types of <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> were not different in patients with or without APLA </plain></SENT>
<SENT sid="4" pm="."><plain>Laboratory assays for APLA were highly positive for only two patients, who both had <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>These results suggest that with the exception of a clinical context of <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> or other <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo>, the usefulness of this diagnostic tool in the management of <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> remains limited </plain></SENT>
</text></document>